For sales

📢Highlights from the Week of June 16 – 23, 2025 in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of June 16 - 23, 2025 Cycle Pharma ( FDA, Approval ) FDA approves HARLIKU™ (nitisinone) as the first and only treatment for ultra‑rare alkaptonuria; U.S. launch set for July 2025 Bayer ( FDA, Approval ) Bayer submits NDA for gadoquatrane at 0.04 mmol/kg, reducing gadolinium exposure by 60% Sanofi & Regeneron ( FDA, Approval ) FDA approves Dupixent as the first and only targeted medicine for bullous pemphigoid in adults Sage Therapeutics + Supernus Pharmaceuticals ( Neuropsychiatry, Acquisition ) Supernus Pharmaceuticals is set to acquire Sage Therapeutics for up to $795 million, adding ZURZUVAE to its neuropsychiatry portfolio All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.